Solid Biosciences (SLDB) Research & Development (2017 - 2026)
Solid Biosciences (SLDB) posted Research & Development of $46.1 million for Q1 2026, up 20.99% sequentially from $38.1 million in Q4 2025, and up 49.25% YoY from $30.9 million in Q1 2025.
Solid Biosciences (SLDB) Research & Development (2017 - 2026) Analysis & Trends
Solid Biosciences has reported Research & Development for 10 years, with the latest figure at $46.1 million in Q1 2026.
- Quarterly Research & Development rose 49.25% year-over-year to $46.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $155.6 million (up 43.4% YoY) and the FY2025 annual result came in at $140.3 million, up 45.52% from the prior year.
- Research & Development advanced to $46.1 million in Q1 2026 per SLDB's latest filing, from $38.1 million in the prior quarter.
- Over five years, Research & Development peaked at $46.1 million in Q1 2026 and troughed at $14.0 million in Q3 2022.
- A 5-year average of $25.8 million and a median of $23.2 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development fell 27.42% in 2023, then jumped 99.12% in 2024.
- Over 5 years, Research & Development stood at $21.3 million in 2022, then dropped by 27.42% to $15.5 million in 2023, then surged by 99.12% to $30.8 million in 2024, then advanced by 23.94% to $38.1 million in 2025, then gained by 20.99% to $46.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $46.1 million, $38.1 million, and $38.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Solid Biosciences | 1.32 Bn | 1.32 Bn | - | 44.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.27 Mn |
| Mar 31, 2026 | 46.14 Mn |
| Dec 31, 2025 | 38.14 Mn |
| Sep 30, 2025 | 38.86 Mn |
| Jun 30, 2025 | 32.42 Mn |
| Mar 31, 2025 | 30.91 Mn |
| Dec 31, 2024 | 30.77 Mn |
| Sep 30, 2024 | 27.33 Mn |
| Jun 30, 2024 | 19.46 Mn |
| Mar 31, 2024 | 18.87 Mn |
| Dec 31, 2023 | 15.45 Mn |
| Sep 30, 2023 | 16.70 Mn |
| Jun 30, 2023 | 19.78 Mn |
| Mar 31, 2023 | 24.63 Mn |
| Dec 31, 2022 | 21.29 Mn |
| Sep 30, 2022 | 14.01 Mn |
| Jun 30, 2022 | 23.18 Mn |
| Mar 31, 2022 | 19.95 Mn |
| Dec 31, 2021 | 14.60 Mn |
| Sep 30, 2021 | 14.43 Mn |